Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Choosing a Prokinetic.

The American journal of gastroenterology·2020
Same author

Meta-analysis of the impact of SPINK1 p.N34S gene variation in Caucasic patients with chronic pancreatitis. An update.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2017
Same author

Low Alcohol and Cigarette Use Is Associated to the Risk of Developing Chronic Pancreatitis.

Pancreas·2016
Same author

Role of Probiotics in Crohn's Disease and in Pouchitis.

Journal of clinical gastroenterology·2015
Same author

Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus Opinion.

Journal of clinical gastroenterology·2015
Same author

Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: Preliminary clinical experience.

Current therapeutic research, clinical and experimental·2014

Related Experiment Video

Updated: May 10, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Microscopic colitis: a therapeutic challenge.

Mario Guslandi

    World Journal of Gastroenterology
    |June 27, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Budesonide is the primary treatment for microscopic colitis, but relapses are common after discontinuation. Long-term budesonide avoidance necessitates exploring alternative therapies due to steroid dependence and toxicity concerns.

    Keywords:
    BudesonideImmunosuppressantsMesalazineMicroscopic colitis

    More Related Videos

    Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
    07:06

    Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

    Published on: December 8, 2014

    Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
    09:01

    Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

    Published on: March 10, 2015

    Related Experiment Videos

    Last Updated: May 10, 2026

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
    05:41

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

    Published on: April 6, 2022

    Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
    07:06

    Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

    Published on: December 8, 2014

    Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
    09:01

    Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

    Published on: March 10, 2015

    Area of Science:

    • Gastroenterology
    • Pharmacology

    Background:

    • Microscopic colitis treatment primarily relies on budesonide, the sole drug proven effective in clinical trials.
    • Budesonide necessitates maintenance therapy (≤6 mg daily) to prevent relapse after initial treatment (9 mg daily).

    Discussion:

    • Long-term budesonide use raises concerns about steroid dependence and drug toxicity.
    • Alternative pharmacological agents are needed to mitigate risks associated with indefinite budesonide treatment.

    Key Insights:

    • Current evidence-based guidelines for alternative microscopic colitis treatments are lacking.
    • Insufficient conclusive data exists regarding immunosuppressive or anti-tumor necrosis factor agents.

    Outlook:

    • Physicians must individualize long-term microscopic colitis management strategies.
    • Further research is crucial to establish evidence-based guidelines for alternative therapies.